Navigation Links
Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm.
Date:11/26/2007

ALBUQUERQUE, N.M., Nov. 26 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com), maker of early-detection cancer diagnostic tests, has approved MicroCap Management as the front-runner of its full media campaign. MicroCap Management has created a strategic media plan that will provide a launch pad for present and future business driven by the progressive vision of Biomoda's Senior Executive Officers.

John Cousins, President of Biomoda announced, "MicroCap has the tools and connections to spread the word to the wider investment community about Biomoda and its potential." Alan Siegel, Managing Director of MicroCap Management, LLC stated: "We are thrilled to have Biomoda on board, and we're extremely enthusiastic about the future of this program."

MicroCap Management, LLC, headquartered in Orlando, Florida, is a Corporate Communications and Broker Relations firm that utilizes business-to-business marketing strategies and extensive relationships with major investment web portals to promote growth for publicly traded companies. Its Managing Directors possess 30+ years experience in marketing and advertising for OTC and Fortune 500 companies, and its highly trained Broker Relations staff has established relationships with broker/dealers nationwide, thereby providing maximum worldwide exposure to broker/dealers, investment bankers, wholesale and retail traders, as well as hedge fund managers and the global investment community.

MicroCap Management has its hands on the pulse of Wall Street, generating exposure and driving liquidity through its free Lead Generator Program and Broker Relations Campaigns; thereby creating a niche that traditional IR and PR firms haven't tapped.

MicroCap Management's core philosophy is to allow its corporate clients to focus on core business while managing its corporate communications and broker relations, and in doing so has frequently taken micro cap companies that were once acorns to a market penetration level of mature oak trees. As a side benefit, these strategies often assist in building the consumer markets as well, which in turn can contribute to increased shareholder equity.

Additionally, MicroCap Management's programs help companies meet pre-requisite criteria to qualify for listing on premier exchanges such as NASDAQ, AMEX and NYSE.

Biomoda's patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive.


'/>"/>
SOURCE Biomoda, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
2. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
3. Vical Names Andrew de Guttadauro Vice President, Corporate Development
4. Signalife Provides Corporate Update
5. Biomira Announces Plan to Reincorporate in the United States
6. Pressure BioSciences, Inc. Provides Corporate Update
7. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
8. Clinsys Clinical Research, Inc. Announces Relocation of Corporate Headquarters
9. ProMed Alliance International Inc. Corporate Name and Trading Symbol Expected to Change Effective Tomorrow
10. MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated
11. New Corporate Website Launched - Focus on Life Scientists, Flow Cytometrists, & Clinicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 2017 NetworkNewsWire Editorial Coverage  ... Cancer remains one ... on health care systems, in terms of costs and resources. ... does the development of innovative and efficient therapies that demonstrate ... many types of cancer treatments, a growing number of patients ...
(Date:3/22/2017)... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a major research ... GSK to generate genetic sequence data from the 500,000 volunteer ... researchers to gain valuable insights to support advances in the ... and life threatening diseases. ... Genetic evidence has revolutionized scientific discovery ...
(Date:3/22/2017)... March 22, 2017 Oramed Pharmaceuticals Inc. ... www.oramed.com ), a clinical-stage pharmaceutical ... delivery systems, announced today that Dr. Miriam ... a presentation titled, "Oral Insulin for Diabetes Treatment: ... Healthtech Institute,s Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... , March 22, 2017   Boston Biomedical , ... therapeutics designed to target cancer stemness pathways, today announced ... Andrews as Chief Executive Officer, effective April 24, ... Chiang J. Li , M.D., FACP, who has led ... ago. Under his leadership, Boston Biomedical has grown from ...
Breaking Biology Technology:
(Date:3/13/2017)... 2017 Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other or ... individuals. (PRNewsFoto/Dermalog Identification Systems) ... "Face Matching" is the fastest software for biometric Face Matching on the market. ...
(Date:3/7/2017)... 7, 2017   HireVue , the leading provider ... identify the best talent, faster, today announced the additions ... (CSO) and Diana Kucer as Chief Marketing ... executive team poised to drive continued growth in the ... year of record bookings in 2017. "Companies ...
(Date:3/2/2017)... 2017 Who risk to be deprived of ... full report: https://www.reportbuyer.com/product/4313699/ WILL APPLE AND ... Fingerprint sensors using capacitive technology represent a fast ... Idex forecasts an increase of 360% of the number ... the fingerprint sensor market between 2014 and 2017 (source ...
Breaking Biology News(10 mins):